



The 40th Annual
High Country
Nuclear
Medicine
Conference

March 2-6, 2019
Vail Marriott, Vail, CO

Saturday, March 2, 2019

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Future of Nuclear Medicine:

Moderators: Michael Wissmeyer, MD and Hans Vija, PhD

Presenters and Topics:

Radiomics, Machine learning

Speaker: TBD

Declining SPECT and the Antidote

Speaker: TBD

Academics vs. Clinics

Speaker: TBD

How to Create Leadership

Speaker: TBD

1:00 pm – 3:00 pm

Roundtable Discussion: TBD

Moderator: TBD

4:00 pm – 7:30 pm

Prostate Cancer Theragnostics

Moderators: Dominique Delbeke, MD and Jim Fletcher, MD

Presenters and Topics

Cellular Metabolism with Choline and ^{18}F -Fluciclovine

Speaker: Jon McConathy (To be confirmed)

Receptor and Membrane Protein Imaging with ^{68}Ga -PSMA and ^{18}F -radiopharmaceuticals: Normal Patterns and Pitfalls

Speaker: TBD

Receptor and Membrane Protein Imaging with ^{68}Ga -PSMA and ^{18}F -radiopharmaceuticals with PET/CT and PET/MRI

Speaker: Jeremie Calais, MD, MSc (Confirmed)

Amino-acid Imaging with Bombesin

Speaker: Hong Song, MD, PhD (Confirmed)

⁶⁸Ga-PSMA Ligands: Impact on Therapy

Speaker: Johannes Czernin (Confirmed)

Radionuclide Therapy including targeted Alpha Therapy with ²²⁵Actinium and ²¹³Bismuth

Speaker: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI (Confirmed)

Panel Discussion

Sunday, March 3, 2019

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Neuroendocrine Tumors Theragnostics

Moderator: Andreas Kjaer, MD

Presenters and Topics

ASTRO-Involvement or the Future of NM

Speaker: TBD

1:00 pm – 3:00 pm

Roundtable Discussion: Regulatory Session

Moderator: Ernest Garcia, PhD

4:00 pm – 6:30 pm

Nuclear Cardiology's Role in the Diagnosis and Management of Cardiac Amyloidosis: Methodology Improvements

Moderator: Daniel Berman, MD and Ernest Garcia, PhD

Cardiac involvement, predominantly due to the deposition of immunoglobulin light chain (Amyloid L, AL) or transthyretin (ATTR), is a major cause of morbidity and mortality in patients with amyloidosis. Improved survival depends on early diagnosis, optimal management of diastolic heart failure, and prevention of a fatal arrhythmia. Advances in disease modifying treatments coupled with improvements in nuclear cardiac imaging methods drive the need in 2019 for earliest possible diagnosis.

Presenters and Topics

Clinical Phenotyping of ATTR with Tc-99m PYP

Speaker: TBD

Planar Tc-99m PYP Imaging Protocol and Multicenter Trial

Speaker: TBD

Simultaneous Dual Isotope Tc-99m PYP/Thallium-201 SPECT Myocardial Imaging

Speaker: Daniel Berman, MD (Confirmed)

Multimodality SPECT/CT Myocardial Imaging

Speaker: Ed Ficaro, PhD (Confirmed)

PET Methods

Speaker: Sharmila Dorbala, MD (Confirmed)

Panel Discussion: Why the Time is Now

7:00pm – 10:00pm

Dinner

Monday, March 4, 2019

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Regulatory and Legislative Update

Session Chairs: Ira Goldman, MA

Moderator: Bob Hendel, MD

Although legislative efforts to repeal and replace the Affordable Care Act are “so 2017,” there continues to be a daily barrage of healthcare developments from the Administration, ranging from efforts at drug pricing reduction, to reform of physician payments, and administration actions to fundamentally change the ACA in the absence of legislative repeal. Increasingly, the major healthcare legislation passed by Congress in past years (PAMA, MACRA) fade from prominence, although the 2019 MPFS proposed has re-emphasized the need for Appropriate Use Criteria (AUC) and Clinical Decision-Support (CDS) systems. Coverage and payment continue to be a major challenge for the future of nuclear medicine, highlighted by CMS’s recent decision to continue not to cover NaF. Thus, this session will provide updates regarding an overview of ongoing legislative and regulatory changes impacting the nuclear medicine sector.

Presenters and Topics

Medical Societies Initiatives on Reimbursement (coverage and payment) and Health Care Policy

Speaker: Satoshi Minoshima, MD, PhD (SNNMI) (To be confirmed)

- Alternate: Munir Ghesani; Sukhjeet Ahuja

Speaker: Kathy Flood (ASNC) (Confirmed)

FDA – Update on FDA Radiopharmaceuticals Review

Speaker: Lou Marzella, MD, PhD, FDA (Confirmed)

Recent Developments Regarding NRC Training and Education Requirements for Alpha and Beta Emitters

Speaker: Dr. Darlene Metter, University of Texas Health Science Center, San Antonio

AUC Status Report – What’s in the Pipeline?

Speaker: Kevin Donohoe, MD (Confirmed)

Comments/Perspective: Bob Hendel

PANELISTS: Bob Hendel, Kathy Flood, Satoshi Minoshima, Kevin Donohoe, Denise Merlino, et. al.

1:00 pm – 3:00 pm

Roundtable Discussion: Future of NM, Prostate Cancer, Neuroendocrine Tumors

Moderator: Michael Wissmeyer, MD

4:00 pm – 7:30 pm

Targeted Radionuclide Therapy, Selection of Radioisotope/Radiopharmaceutical

Moderator: Alan Packard, PhD, and Kevin Donohoe, MD

Targeted radionuclide therapy is an area of increasing interest within the nuclear medicine community: For the first time since the introduction of radioiodine therapy, novel radiopharmaceuticals are being developed that allow nuclear medicine physicians not only to diagnose, but to treat, disease. Accompanying this increased interest, however, is a fundamental question: Which radionuclide(s) are the most effective at treating disease. While previous discussions focused on the relative merits of high-energy versus lower-energy β - emitters, the question has now broadened to include the relative merits of α emitters vs. β - emitters and Auger and conversion electron emitters such as ^{117}Sn . This session will focus on the underlying principles necessary to address these questions, from the challenges of attaching alpha emitters to targeting vectors, to the relative merits of high LET versus lower LET particles, to the challenges of moving these new agents into the clinic.

Presenters and Topics

Radionuclide Supply

Speaker: Roy W. Brown, BS, MBA (Confirmed)

Radiopharmaceutical Development – The Challenges of Alpha Emitters

Speaker: TBD

Moving from the Lab to the Clinic – A Radiopharmacist’s Perspective

Speaker: TBD

Clinical Experience with Targeted Alpha-Emitting Radiopharmaceuticals

Speaker: TBD

Clinical Experience with Targeted Beta-Emitting Radiopharmaceuticals

Speaker: TBD

Tuesday, March 5, 2019

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Imaging the Immune System and Infection

Moderators: Dominique Delbeke, MD, PhD and Andreas Kjaer, MD

Presenters and Topics:

Molecular Imaging of Immunotherapy Targets in Cancer

Speaker: TBD

Non-invasive Molecular Imaging Using Reporter Genes

Speaker: TBD

Immune Checkpoint Blockade in Hematological Malignancies

Speaker: TBD

CAR T-cell Therapy: Toxicity and Management

Speaker: TBD

Dendritic Cell Vaccine

Speaker: TBD

Immunodeficiency and Infections

Speaker: TBD

1:00 pm – 3:00 pm

Roundtable Discussion: Amyloidosis, Therapy, Neuro

Moderator: TBD

4:00 pm – 7:30 pm

Which PET Instrumentation and Reconstruction Options for Neuronuclear Imaging?

Moderator: Daniel Silverman, MD, PhD

Presenters and Topics:

PET/CT vs. PET/MRI?

Speaker: TBD

Dedicated Head PET vs. Hybrid Imaging?

Speaker: TBD

Attenuation Correction Algorithms -- Calculated and Measured?

Speaker: TBD

Wednesday, March 6, 2019

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Technical, Scientific and Clinical Considerations for Measuring MBF and MFR with SPECT Tracers:

Moderator: Ernest V Garcia, PhD a and Hans Vija, PhD

SPECT MPI's clinical approach to quantifying hypoperfusion has depended on normal databases where a patient's left ventricular perfusion pattern is statistically compared to an expected normal perfusion pattern generated from patients with a low likelihood of CAD. Recent innovations are poised to bring SPECT MPI to the next level by using dynamic SPECT with a SPECT/CT camera to measure absolute myocardial blood flow (MBF) and MBF reserve (MFR). The speakers in this session will address whether the SPECT flow quantitation method is a clinically effective approach to enhancing CAD detection. Specifically, this session will address whether existing SPECT cameras, tracers, protocols and image analysis are adequate to increase the accuracy of CAD evaluation beyond the present relative techniques. This session will ask whether SPECT measurements of MBF and MBFR are ready for clinical use, and how will the SPECT measurements compare to PET MBF and MFR?

Presenters and Topics:

Technical Considerations

R. Glenn Wells, PhD (Confirmed)

Cameras' Performance

Piotr Slomka, PhD (Confirmed)

Imaging Protocols

Grant Gullberg, PhD (Confirmed)

Reconstruction and Flow Measurements

Edward Ficaro, PhD (Confirmed)

Clinical SPECT Applications/ Comparisons to PET

Venkatesh Murthy, MD (Confirmed)

Panel: Are SPECT measurements of MBF and MFR ready for clinical use?